🔗 Share this article

A top medical figure has been removed of involvement in a major clinical trial into gender-affirming medication after accusations of bias came to light.

Alleged Intervention Resulted in Study Pause

Per media reports, Prof Jacob George, a head medical director at the MHRA, voiced worries which resulted in the pausing of the government-backed Pathways trial in early 2024.

The regulator declared recently that George was recusing him from participation with the study after questioning online remarks posted in the past were identified.

Content of Online Comments

Among a statement, George referred to author the Harry Potter author as a valuable figure of our time.” Elsewhere, the professor commented how the rejection of basic biological fact was troubling” in regards to discussions about a elite boxer’s sex.

This regulator clarified that even though the comments occurred prior to his official position, he had been taken off of involvement in the trial as a abundance of caution.

Details of the Paused Pathways Trial

This clinical study, that was intended to evaluate the impact of hormone suppressants for young people questioning their gender identity, was due to begin enrolling subjects during January.

However, the trial was suspended in February when its medicines regulator raised worries over the safety for adolescents involved.

• Its youngest participants were projected to be 10 to 11 among girls and 11 to 12 for boys.
• Its research organizers said earlier that the thorough selection process suggested those enrolled would probably be of a higher age.
• But, the agency have since stated the minimum age limit must be 14 due to an unknown danger” for enduring biological harms.”

This clinical trial had planned to enroll a projected two hundred and twenty-six youths over the coming 36 months.

Context and a Cass Review

This trial was initiated subsequent to a recommendation from an independent inquiry into children’s gender care, which found that the robustness of the research suggesting to show the benefits of such drugs in children with gender incongruence were low-quality.”

Dr Hilary Cass, who headed that review, once said her report exposed a notably limited evidence base” supporting the usefulness of puberty blockers.

She continued, “given that there are doctors, children and parents that believe deeply of the positive outcomes, research remained the necessary step ahead to understand the situation.”

Medical Concern of the Action

Dr Max Davie, a child health specialist, said there was no convincing medical rationale to suspend the trial.

“The social media posts from Prof George give a transparent view into his own opinions regarding gender identity,” he said. “The professor is entitled to possess any opinions about gender identity he chooses, however what he cannot do is let these beliefs to influence the execution of his official role.”

He added: “To be clear, there is no compelling research justification to pause the Pathways trial. While Prof George’s own views are not the sole possible explanation for the regulator’s sudden volte-face, it is the single factor for which supporting information.”

Regulator Response Regarding Future Actions

A regulatory spokesperson said: “With every medical studies, the MHRA’s foremost duty remains the protection and welfare for the volunteers. As part of this duty, complicated studies remain constantly being monitored while the MHRA maintains an active scientific dialogue alongside trial sponsors.”

“The MHRA have world-class medical, scientific and regulatory specialists who work as a multidisciplinary team to deliver research-informed decisions regarding clinical trials. These individuals will continue to engage with the research team to work through the subsequent actions in a positive manner.”

“Subsequent to the discovery regarding online activity made prior to his appointment, Professor Jacob George is recused from continued participation regarding this study as a preventative step.”